Harnessing the power of RNA epigenetics

Watch full video

STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

Read more

RNA and RNA epigenetics

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template for the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more

News

STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences

STORM Therapeutics and the University of Cambridge receive Innovate UK funding to help the fight against cancer

Events

20th June 2019 | Cambridge, UK

SCI New Approaches in Medicinal Chemistry III

25 - 27th June 2019 | Weizmann, Israel

Weizmann Institute, RNA modifications: Form, function and mechanism

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 17-20 September 2019

Find out more

Speakers

  • Reuven Agami
  • Shankar Balasubramanian
  • Thomas Carell
  • Robert Copeland
  • Tom Cech
  • Michaela Frye
  • Francois Fuks
  • Richard Gregory
  • Chuan He
  • Stacy Horner
  • Samie Jaffrey
  • Narry Kim
  • Jeannie Lee
  • Michal Minczuk
  • Gidi Rechavi
  • Tom Suzuki